BioCentury | Jul 17, 2018
Distillery Therapeutics

Endocrine/Metabolic

...GLIS3-mutant diabetes. Screening of a library of approved drugs, drug-like compounds and tool compounds in GLIS3-knockout...
...of apoptosis and necrosis. Next steps could include testing TGFBR1 inhibitors in animal models of GLIS3-mutant...
...cancer and idiopathic pulmonary fibrosis (IPF). TARGET/MARKER/PATHWAY: Transforming growth factor β receptor 1 (TGFBR1; ALK5); GLIS family zinc finger 3 (GLIS3)...
BioCentury | Apr 7, 2016
Translation in Brief

Knowing when to fold

...complementing defective repair in Chinese hamster cells 4 (XRCC4) gene and decreased expression of the GLIS family zinc finger 3 (GLIS3)...
...a binding partner of a DNA ligase that repairs DNA breaks in β cells and GLIS3...
...cell death in a mouse model of Type II diabetes, which was associated with reduced GLIS3...
BioCentury | Apr 7, 2016
Distillery Techniques

Disease models

...therapies to treat Type I and Type II diabetes. In mice, systemic heterozygous knockout of GLIS3...
...treat late-stage β cell death in diabetes (see "Knowing When to Fold," page 16). DESCRIPTION: GLIS family zinc finger 3 (GLIS3)-knockout...
BioCentury | Nov 29, 2012
Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Core-binding factor runt domain a-subunit 2 translocated to 3 (CBFA2T3)-GLIS family zinc finger 2 (GLIS2) fusion protein as a biomarker for non-Down syndrome acute megakaryoblastic leukemia...
BioCentury | Jun 4, 2009
Distillery Therapeutics

Indication: Endocrine disease

...Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes IL-10; IL-19; IL-20; IL-27; GLIS family zinc finger 3 (GLIS3)...
...the identified loci that had relevance to type 1 diabetes include IL-10, IL-19, IL-20, IL-27, GLIS3...
Items per page:
1 - 5 of 5